Uliledlimab is an antibody designed to target CD73. The development pause will also allow I-Mab to allow data from an ongoing ...

Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a ...

Invenra has launched its Rapid Antibody Discovery Service, designed to simplify and de-risk the preclinical development of ...

ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China ImmuneOnc ...

Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its fully human antibodies to ...

Boehringer Ingelheim has acquired a licence for the development of antibody-based cancer treatments from Oxford ...

Achievement strengthens iBio’s partnered cardiometabolic and obesity program while showcasing its proprietary AI-driven drug ...

A panelist discusses how loncastuximab tesirine, an antibody-drug conjugate targeting CD19, shows promise in combination with ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the ...

Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...

Scientists from Duke-NUS Medical School and the Singapore General Hospital have discovered that T cells—white blood cells ...

Telix Pharmaceuticals (ASX:TLX) enters into an asset purchase agreement with antibody engineering company ImaginAb.